Clinical, laboratory and instrumental evaluation of structural and functional changes of the liver in patients with heart failure

Abstract

Heart failure is detected in 2% of the population. The leading causes of heart failure are coronary heart disease, arterial hypertension, and valvular heart disease. The number of patients with chronic heart failure continues to increase despite the new methods of diagnosis and treatment. A special contribution is made by damage to target organs in the development of cardiovascular pathology. Impaired liver function or congestive liver is common in heart failure and increases the risk of death and requires further study. The mechanism of liver damage in chronic heart failure is complex and multicomponent. The sensitivity and specificity of standard clinical, laboratory and instrumental methods for the diagnosis of congestive liver are insufficient. With the increase, severity and duration of venous congestion, structural changes in the architectonics occur, leading to the formation of liver fibrosis. The development of cardiac liver fibrosis leads to a complication of the course of chronic heart failure and an increase in mortality.

Among the new diagnostic methods, the most important are serological markers of liver fibrosis, which have high diagnostic accuracy, as well as histological determination of fibrosis, as well as ultrasound examination of the liver in B-mode and determination of liver stiffness by elastography. Direct and indirect serological markers have a higher diagnostic value when using their combination in the composition of panels in the development of hepatopathy of different origins. An increase in the concentration of markers of fibrosis and liver stiffness during elastography correlates with the severity of heart failure and a long-term prognosis for mortality, including from extrahepatic diseases. Performing liver elastography in dynamics allows to monitor the course and treatment of heart failure. The optimal diagnostic method is a combination of direct and indirect markers of fibrosis, ultrasound diagnostics and elastography, in addition to clinical assessment of signs and direct assessment of hemodynamic parameters.

Keywords

chronic heart failure / congestive liver / serological markers of liver fibrosis / ultrasound examination of the liver / elastography / liver stiffness / cardiac liver fibrosis

References

[1] Metra M, Teerlink JR. Heart Failure. Lancet. 2017;390(10106):1981–1995. DOI: 10.1016/s0140-6736(17)31071-1

[2] Metra M., Teerlink J.R. Heart Failure // Lancet. 2017. Vol. 390, No. 10106. P. 1981–1995. DOI: 10.1016/s0140-6736(17)31071-1

[3] Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatmtnt of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with special contribution of the heart failure assotiation (HFA) of the ESC. Eur J Heart Fail. 2016;37(27):2129–2200. DOI: 10.1093/eurheartj/ehw128

[4] Ponikowski P., Voors A.A., Anker S.D. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with special contribution of the heart failure assotiation (HFA) of the ESC // Eur. J. Heart Fail. 2016. Vol. 37, No. 27. P. 2129–2200. DOI: 10.1093/eurheartj/ehw128

[5] Fomin IV. Chronic heart failure in russian federation: what do we know and what to do. Russian Journal of Cardiology. 2016;21(8):7–13. (In Russ.). DOI: 10.15829/1560-4071-2016-8-7-13

[6] Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что мы сегодня знаем и что должны делать // Российский кардиологический журнал. 2016. Т. 21, № 8. С. 7–13. DOI: 10.15829/1560-4071-2016-8-7-13

[7] Ketsum ES, Levy WC. Establising prognosing in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011;54(2):86–96. DOI: 10.1016/j.pcad.2011.03.003

[8] Ketsum E.S., Levy W.C. Establising prognosing in heart failure: a multimarker approach // Prog. Cardiovasc. Dis. 2011. Vol. 54, No. 2. P. 86–96. DOI: 10.1016/j.pcad.2011.03.003

[9] Fortea JI, Puente A, Cuadrado A, et al. Cardiac Hepatopathy. Intech Open. 2019. DOI: 10.5772/intechopen.89177

[10] Fortea J.I., Puente A., Cuadrado A. et al. Cardiac Hepatopathy. Intech Open. 2019. DOI: 10.5772/intechopen.89177

[11] Sherlock S. The liver in heart failure: relation of anatomical, functional, and circulatory changes. Br Heart J. 1951;13(3):273–293. DOI: 10.1136/hrt.13.3.273

[12] Sherlock S. The liver in heart failure: relation of anatomical, functional, and circulatory changes // Br. Heart J. 1951. Vol. 13, No. 3. P. 273–293. DOI: 10.1136/hrt.13.3.273

[13] Shah SC, Sass DA. “Cardiac hepatopathy”: a review of liver dysfunction in heart failure. Liver Res Open J. 2015;1(1):1–10. DOI: 10.17140/lroj-1-101

[14] Shah S.C., Sass D.A. “Cardiac hepatopathy”: a review of liver dysfunction in heart failure // Liver Res. Open J. 2015. Vol. 1, No. 1. P. 1–10. DOI: 10.17140/lroj-1-101

[15] Van Deursen VM, Damman K, Hillege HL, et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010;16(1):84–90. DOI: 10.1016/j.cardfail.2009.08.002

[16] van Deursen V.M., Damman K., Hillege H.L. et al. Abnormal liver function in relation to hemodynamic profile in heart failure patients // J. Card. Fail. 2010. Vol. 16, No. 1. P. 84–90. DOI: 10.1016/j.cardfail.2009.08.002

[17] Moller S, Bernardi M. Interaction of the heart and the liver. Eur Heart J. 2013;34(36):2804–2811. DOI: 10.1093/eurheartj/eht246

[18] Moller S., Bernardi M. Interaction of the heart and the liver // Eur. Heart J. 2013. Vol. 34, No. 36. P. 2804–2811. DOI: 10.1093/eurheartj/eht246

[19] Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions. JACC Heart Fail. 2019;7(2):87–97. DOI: 10.1016/j.jchf.2018.10.007

[20] Xanthopoulos A., Starling R.C., Kitai T., Triposkiadis F. Heart failure and liver disease: cardiohepatic interactions // JACC Heart Fail. 2019. Vol. 7, No. 2. P. 87–97. DOI: 10.1016/j.jchf.2018.10.007

[21] Yoshihisa A, Sato Y, Yokokawa T, et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5(2):262–270. DOI: 10.1002/ehf2.12222

[22] Yoshihisa A., Sato Y., Yokokawa T. et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction // ESC Heart Fail. 2018. Vol. 5, No. 2. P. 262–270. DOI: 10.1002/ehf2.12222

[23] Hisler M, Sanchez W. Congestive hepatopathy. Clin Liver Dis (Hoboken). 2016;8(3):68–71. DOI: 10.1002/cld.573

[24] Hisler M., Sanchez W. Congestive hepatopathy // Clin. Liver Dis. (Hoboken). 2016. Vol. 8, No. 3. P. 68–71. DOI: 10.1002/cld.573

[25] Koehne de Gonzarez AK, Lewkowitch JH. Heart diseases and the liver: pathologic evaluation. Gastroenterol Clin North Am. 2017;46(2):421–435. DOI: 10.1016/j.gtc.2017.01.012

[26] Koehne de Gonzarez A.K., Lewkowitch J.H. Heart diseases and the liver: pathologic evaluation // Gastroenterol. Clin. North Am. 2017. Vol. 46, No. 2. P. 421–435. DOI: 10.1016/j.gtc.2017.01.012

[27] Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist point of view. Int J Cardiol. 2013;166(3):554–558. DOI: 10.1016/j.ijcard.2012.05.003

[28] Kavoliuniene A., Vaitiekiene A., Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist point of view // Int. J. Cardiol. 2013. Vol. 166, No. 3. P. 554–558. DOI: 10.1016/j.ijcard.2012.05.003

[29] Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlation. Hepatology. 2003;37(2):393–400. DOI: 10.1053/jhep.2003.50062

[30] Myers R.P., Cerini R., Sayegh R. et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlation // Hepatology. 2003. Vol. 37, No. 2. P. 393–400. DOI: 10.1053/jhep.2003.50062

[31] Farias AQ, Silvestre OM, Garsia-Tsao G, et al. Serum B-type natriuretic peptide in the initial workup of patients with new onset ascitis: a diagnostic accuracy study. Hepatology. 2014;59(3):1043–1051. DOI: 10.1002/hep.26643

[32] Farias A.Q., Silvestre O.M., Garsia-Tsao G. et al. Serum B-type natriuretic peptide in the initial workup of patients with new onset ascitis: a diagnostic accuracy study // Hepatology. 2014. Vol. 59, No. 3. P. 1043–1051. DOI: 10.1002/hep.26643

[33] Lemmer A, Van-Wagner L, Ganger D. Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy. Hepatology. 2018;68(4):1633–1641. DOI: 10.1002/hep.30048

[34] Lemmer A., Van-Wagner L., Ganger D. Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy // Hepatology. 2018. Vol. 68, No. 4. P. 1633–1641. DOI: 10.1002/hep.30048

[35] Denis C, De Kerguennec C, Bernuau J, et al. Acute hypoxic hepatitis (‘liver shock’): still a frequently overlooked cardiological diagnosis. Eur J Heart Fail. 2004;6(5):561–565. DOI: 10.1016/j.ejheart.2003.12.008

[36] Denis C., De Kerguennec C., Bernuau J. et al. Acute hypoxic hepatitis (‘liver shock’): still a frequently overlooked cardiological diagnosis // Eur. J. Heart Fail. 2004. Vol. 6, No. 5. P. 561–565. DOI: 10.1016/j.ejheart.2003.12.008

[37] Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Investig. 2012;42(2):153–163. DOI: 10.1111/j.1365-2362.2011.02573.x

[38] Poelzl G., Ess M., Mussner-Seeber C. et al. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance // Eur. J. Clin Investig. 2012. Vol. 42, No. 2. P. 153–163. DOI: 10.1111/j.1365-2362.2011.02573.x

[39] Ess M, Mussner-Seeber C, Mariacher S, et al. G-glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure. J Card Fail. 2011;17(7):577–584. DOI: 10.1016/j.cardfail.2011.02.012

[40] Ess M., Mussner-Seeber C., Mariacher S. et al. G-glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure // J. Card. Fail. 2011. Vol. 17, No. 7. P. 577–584. DOI: 10.1016/j.cardfail.2011.02.012

[41] Poelzl G, Eberl C, Achrainer H, et al. Prevalence and prognostic significance of elevated-glutamyltransferase in chronic heart failure. Circ. Heart Fail. 2009;2(4):294–302. DOI: 10.1161/circheartfailure.108.826735

[42] Poelzl G., Eberl C., Achrainer H. et al. Prevalence and prognostic significance of elevated-glutamyltransferase in chronic heart failure // Circ. Heart Fail. 2009. Vol. 2, No. 4. P. 294–302. DOI: 10.1161/circheartfailure.108.826735

[43] Shinagava H, Inomata T, Koitabashi T, et al. Increased serum bilirubin levels coincident with heart failure decompensation indicate the need for intravenous inotropic agents. Int Heart J. 2007;48(2):195–204. DOI: 10.1536/ihj.48.195

[44] Shinagava H., Inomata T., Koitabashi T. et al. Increased serum bilirubin levels coincident with heart failure decompensation indicate the need for intravenous inotropic agents // Int. Heart J. 2007. Vol. 48, No. 2. P. 195–204. DOI: 10.1536/ihj.48.195

[45] Bradley E, Hendrickson B, Daniels C. Fontan liver disease: review of an emerging epidemic and management options. Curr Treat Options Cardiovasc Med. 2015;17(11):51. DOI: 10.1007/s11936-015-0412-z

[46] Bradley E., Hendrickson B., Daniels C. Fontan liver disease: review of an emerging epidemic and management options // Curr. Treat Options Cardiovasc. Med. 2015. Vol. 17, No. 11. P. 51. DOI: 10.1007/s11936-015-0412-z

[47] Wu FM, Kogon B, Earing MG, et al. Liver health in adults with Fontan circulation: A multicenter cross-sectional study. J Thorac Cardiovasc Surg. 2017;153(3):656–664. DOI: 10.1016/j.jtcvs.2016.10.060

[48] Wu FM., Kogon B., Earing MG. et al. Liver health in adults with Fontan circulation: A multicenter cross-sectional study // J. Thorac. Cardiovasc. Surg. 2017. Vol. 153, No. 3. P. 656–664. DOI: 10.1016/j.jtcvs.2016.10.060

[49] Amin A, Vakilian F, Maleki M. Serum uric acid levels correlate with filling pressures in systolic heart failure. Congest Heart Fail. 2011;17(2):80–84. DOI: 10.1111/j.1751-7133.2010.00205.x

[50] Amin A., Vakilian F., Maleki M. Serum uric acid levels correlate with filling pressures in systolic heart failure // Congest. Heart Fail. 2011. Vol. 17, No. 2. P. 80–84. DOI: 10.1111/j.1751-7133.2010.00205.x

[51] Wells ML, Venkatech SK. Congestive hepatopathy. Abdom Radiol (NY). 2018;43(8):2031–2051. DOI: 10.1007/s00261-017-1387-x

[52] Wells M.L., Venkatech S.K. Congestive hepatopathy // Abdom. Radiol. (NY). 2018. Vol. 43, No. 8. P. 2031–2051. DOI: 10.1007/s00261-017-1387-x

[53] Abraldes JG, Sarlieve P, Tandon P. Measurement of portal pressure. Clin Liver Dis. 2014;18(4):779–792. DOI: 10.1016/j.cld.2014.07.002

[54] Abraldes J.G., Sarlieve P., Tandon P. Measurement of portal pressure // Clin. Liver Dis. 2014. Vol. 18, No. 4. P. 779–792. DOI: 10.1016/j.cld.2014.07.002

[55] Dhall D, Kim SA, Mc Phaul C, et al. Heterogeneity of fibrosis in liver biopsies of patients with heart failure undergoing heart transplant evaluation. Am J Surg Pathol. 2018;42(12):1617–1624. DOI: 10.1097/pas.0000000000001163

[56] Dhall D., Kim S.A., Mc Phaul C. et al. Heterogeneity of fibrosis in liver biopsies of patients with heart failure undergoing heart transplant evaluation // Am. J. Surg. Pathol. 2018. Vol. 42, No. 12. P. 1617–1624. DOI: 10.1097/pas.0000000000001163

[57] Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic interaction in heart failure: an overwiew and clinical implications. J Am Coll Cardiol. 2013;61(24):2397–2405. DOI: 10.1016/j.jacc.2013.03.042

[58] Samsky M.D., Patel C.B., DeWald T.A. et al. Cardiohepatic interaction in heart failure: an overwiew and clinical implications // J. Am. Coll. Cardiol. 2013. Vol. 61, No. 24. P. 2397–2405. DOI: 10.1016/j.jacc.2013.03.042

[59] Bosch DE, Koro K, Richards E, et al. Validation of a congestive hepatic fibrosis score system. Am J Surg Pathol. 2019;43(6):766–772. DOI: 10.1097/pas.0000000000001250

[60] Bosch D.E., Koro K., Richards E. et al. Validation of a congestive hepatic fibrosis score system // Am. J. Surg. Pathol. 2019. Vol. 43, No. 6. P. 766–772. DOI: 10.1097/pas.0000000000001250

[61] Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? Front Pharmacol. 2016;7:159. DOI: 10.3389/fphar.2016.00159

[62] Chin J.L., Pavlides M., Moolla A., Ryan J.D. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? // Front. Pharmacol. 2016. Vol. 7. P. 159. DOI: 10.3389/fphar.2016.00159

[63] Veidal SS, Bay-Jensen AC, Tougas G, et al. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers. 2010;28(1):15–28. DOI: 10.3233/DMA-2010-0678

[64] Veidal S.S., Bay-Jensen A.C., Tougas G. et al. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers // Dis. Markers. 2010. Vol. 28, No. 1. P. 15–28. DOI: 10.3233/DMA-2010-0678

[65] Henderson NC, Arnold TD, Katamura Y, et al. Targeting of av integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 2013;19(12):1617–1624. DOI: 10.1038/nm.3282

[66] Henderson N.C., Arnold T.D., Katamura Y. et al. Targeting of av integrin identifies a core molecular pathway that regulates fibrosis in several organs // Nat. Med. 2013. Vol. 19, No. 12. P. 1617–1624. DOI: 10.1038/nm.3282

[67] Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381(12):107–113. DOI: 10.1016/j.cca.2007.02.038

[68] Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests // Clin. Chim. Acta. 2007. Vol. 381, No. 12. P. 107–113. DOI: 10.1016/j.cca.2007.02.038

[69] EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237–264. DOI: 10.1016/j.jhep.2015.04.006

[70] EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis // J. Hepatol. 2015. Vol. 63, No. 1. P. 237–264. DOI: 10.1016/j.jhep.2015.04.006

[71] Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholicfatty liver disease. J Hepatol. 2016;65(3):570–578. DOI: 10.1016/j.jhep.2016.04.023

[72] Boursier J., Vergniol J., Guillet A. et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholicfatty liver disease // J. Hepatol. 2016. Vol. 65, No. 3. P. 570–578. DOI: 10.1016/j.jhep.2016.04.023

[73] Genkel’ VV, Hasanova RO, Koljadich MI. Determinants of increased serum markers of liver fibrosis in patients with chronic heart failure. Experimental and Clinical Gastroenterology Journal. 2019;(6(166)):37–43. (In Russ.). DOI: 10.31146/1682-8658-ecg-166-6-37-43

[74] Генкель В.В., Хасанова Р.О., Колядич М.И. Детерминанты увеличения серологических маркеров фиброза печени у пациентов с хронической сердечной недостаточностью // Экспериментальная и клиническая гастроэнтерология. 2019. № 6(166). С. 37–43. DOI: 10.31146/1682-8658-ecg-166-6-37-43

[75] Stolbova SK, Dragomiretskaya NА, Beliaev IG, Podzolkov VI. Clinical and laboratory associations of liver fibrosis indexes in patients with decompensated chronic heart failure II-IV functional classes. Kardiologiia. 2020;60(5):90–99. (In Russ.). DOI: 10.18087/cardio.2020.5.n920

[76] Столбова C.К., Драгомирецкая Н.А., Беляев Ю.Г., Подзолков В.И. Клинико-лабораторные ассоциации индексов печеночного фиброза у больных с декомпенсацией хронической сердечной недостаточности II–IV функциональных классов // Кардиология. 2020. Т. 60, № 5. С. 90–99. DOI: 10.18087/cardio.2020.5.n920

[77] Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067. DOI: 10.1016/j.jhepr.2020.100067

[78] Patel K., Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis // JHEP Rep. 2020. Vol. 2, No. 2. P. 100067. DOI: 10.1016/j.jhepr.2020.100067

[79] Ozturk A, Grajo JR, Dhyani M, et al. Principles of ultrasound elastography. Abdom Radiol (NY). 2018;43(4):773–785. DOI: 10.1007/s00261-018-1475-6

[80] Ozturk A., Grajo J.R., Dhyani M. et al. Principles of ultrasound elastography // Abdom. Radiol. (NY). 2018. Vol. 43, No. 4. P. 773–785. DOI: 10.1007/s00261-018-1475-6

[81] Shiina T, Nightingale KR, Palmeri ML, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 1: basic principles and terminology. Ultrasound Med Biol. 2015;41(5):1126–1147. DOI: 10.1016/j.ultrasmedbio.2015.03.009

[82] Shiina T., Nightingale K.R., Palmeri M.L. et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 1: basic principles and terminology // Ultrasound. Med. Biol. 2015. Vol. 41, No. 5. P. 1126–1147. DOI: 10.1016/j.ultrasmedbio.2015.03.009

[83] Babu AS, Wells ML, Teytelboym OM, et al. Elastography in chronic liver disease: modalities, techniques, limitations and future directions. Radiographics. 2016;36(7):1987–2006. DOI: 10.1148/rg.2016160042

[84] Babu A.S., Wells M.L., Teytelboym O.M. et al. Elastography in chronic liver disease: modalities, techniques, limitations and future directions // Radiographics. 2016. Vol. 36, No. 7. P. 1987–2006. DOI: 10.1148/rg.2016160042

[85] Ferraioli G, Barr RG. Ultrasound liver elastography beyond liver fibrosis assessment. World J Gastroenterol. 2020;26(24):3413–3420. DOI: 10.3748/wjg.v26.i24.3413

[86] Ferraioli G., Barr R.G. Ultrasound liver elastography beyond liver fibrosis assessment // World J. Gastroenterol. 2020. Vol. 26, No. 24. P. 3413–3420. DOI: 10.3748/wjg.v26.i24.3413

[87] Lebray P, Varnous S, Charlotte F, et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology. 2008;48(6):2089. DOI: 10.1002/hep.22594

[88] Lebray P., Varnous S., Charlotte F. et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency // Hepatology. 2008. Vol. 48, No. 6. P. 2089. DOI: 10.1002/hep.22594

[89] Millonig G, Friedrich S, Adolf S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol. 2010;52(2):206–210. DOI: 10.1016/j.jhep.2009.11.018

[90] Millonig G., Friedrich S., Adolf S. et al. Liver stiffness is directly influenced by central venous pressure // J. Hepatol. 2010. Vol. 52, No. 2. P. 206–210. DOI: 10.1016/j.jhep.2009.11.018

[91] Taniguchi T, Sakata Y, Ohtani T, et al. Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure. Am J Cardiol. 2014;113(3):552–558. DOI: 10.1016/j.amjcard.2013.10.018

[92] Taniguchi T., Sakata Y., Ohtani T. et al. Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure // Am. J. Cardiol. 2014. Vol. 113, No. 3. P. 552–558. DOI: 10.1016/j.amjcard.2013.10.018

[93] Taniguchi T, Ohtani T, Kioka H, et al. Liver stiffness reflecting right-sided filling pressure can predict adverse outcomes in patients with heart failure. JACC Cardiovasc Imaging. 2019;12(6):955–964. DOI: 10.1016/j.jcmg.2017.10.022

[94] Taniguchi T., Ohtani T., Kioka H. et al. Liver stiffness reflecting right-sided filling pressure can predict adverse outcomes in patients with heart failure // JACC Cardiovasc. Imaging. 2019. Vol. 12, No. 6. P. 955–964. DOI: 10.1016/j.jcmg.2017.10.022

[95] Omote K, Nagai T, Asakawa N, et al. Impact of admission liver stiffness on long-term clinical outcomes in patients with acute decompensated heart failure. Heart Vessels. 2019;34(6):984–991. DOI: 10.1007/s00380-018-1318-y

[96] Omote K., Nagai T., Asakawa N. et al. Impact of admission liver stiffness on long-term clinical outcomes in patients with acute decompensated heart failure // Heart Vessels. 2019. Vol. 34, No. 6. P. 984–991. DOI: 10.1007/s00380-018-1318-y

[97] Saito Y, Kato M, Nagashima K, et al. Prognostic relevance of liver stiffness assessed by transient elastography in patients with acute decompensated heart failure. Circ J. 2018;82(7):1822–1829. DOI: 10.1253/circj.cj-17-1344

[98] Saito Y., Kato M., Nagashima K. et al. Prognostic relevance of liver stiffness assessed by transient elastography in patients with acute decompensated heart failure // Circ. J. 2018. Vol. 82, No. 7. P. 1822–1829. DOI: 10.1253/circj.cj-17-1344

[99] Colli A, Pozzoni P, Berzuini A, et al. Decompensated chronic heart failure: Increased liver stiffness measured by means of transient elastography. Radiology. 2010;257(3):872–878. DOI: 10.1148/radiol.10100013

[100] Colli A., Pozzoni P., Berzuini A. et al. Decompensated chronic heart failure: Increased liver stiffness measured by means of transient elastography // Radiology. 2010. Vol. 257, No. 3. P. 872–878. DOI: 10.1148/radiol.10100013

[101] Alegre F, Herrero JI, Iñarrairaegui M, et al. Increased liver stiffness values in patients with heart failure. Acta Gastroenterol Belg. 2013;76(2):246–250.

[102] Alegre F., Herrero J.I., Iñarrairaegui M. et al. Increased liver stiffness values in patients with heart failure // Acta Gastroenterol. Belg. 2013. Vol. 76, No. 2. P. 246–250.

[103] Solov’eva AE, Kobalava ZhD, Villeval’de SV, et al. Prognostic value of liver stiffness in decompensated heart failure: results of prospective observational transient elastography-based study. Kardiologija. 2018;58(S10):20–32. (In Russ.). DOI: 10.18087/cardio.2488

[104] Соловьева А.Е., Кобалава Ж.Д., Виллевальде С.В. и др. Прогностическое значение плотности печени при декомпенсации сердечной недостаточности: результаты проспективного наблюдательного исследования, основанные на данных непрямой эластометрии // Кардиология. 2018. Т. 58, № S10. С. 20–32. DOI: 10.18087/cardio.2488

[105] Potthoff A, Schettler A, Attia D, et al. Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. J Heart Lung Transplant. 2015;34(12):1586–1594. DOI: 10.1016/j.healun.2015.05.022

[106] Potthoff A., Schettler A., Attia D. et al. Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study // J. Heart Lung Transplant. 2015. Vol. 34, No. 12. P. 1586–1594. DOI: 10.1016/j.healun.2015.05.022

[107] Nishi H, Toda K, Miyagawa S, et al. Novel method of evaluating liver stiffness using transient elastography to evaluate perioperative status in severe heart failure. Circ J. 2015;79(2):391–397. DOI: 10.1253/circj.cj-14-0929

[108] Nishi H., Toda K., Miyagawa S. et al. Novel method of evaluating liver stiffness using transient elastography to evaluate perioperative status in severe heart failure // Circ. J. 2015. Vol. 79, No. 2. P. 391–397. DOI: 10.1253/circj.cj-14-0929

[109] Fang C, Konstantatou E, Romanos O, et al. Reproducibility of 2-dimensional shear wave elastography assessment of the liver: a direct comparison with point shear wave elastography in healthy volunteers. J Ultrasound Med. 2017;36(8):1563–1569. DOI: 10.7863/ultra.16.07018

[110] Fang C., Konstantatou E., Romanos O. et al. Reproducibility of 2-dimensional shear wave elastography assessment of the liver: a direct comparison with point shear wave elastography in healthy volunteers // J. Ultrasound. Med. 2017. Vol. 36, No. 8. P. 1563–1569. DOI: 10.7863/ultra.16.07018

[111] Avila DX, Matos PA, Quintino G, et al. Diagnostic and prognostic role of liver elastography in heart failure. Int J Cardiovasc Sci. 2019;33(3):227–232. DOI: 10.36660/ijcs.20190005

[112] Avila D.X., Matos P.A., Quintino G. et al. Diagnostic and prognostic role of liver elastography in heart failure // Int. J. Cardiovasc. Sci. 2019. Vol. 33, No. 3. P. 227–232. DOI: 10.36660/ijcs.20190005

[113] Balashova AA, Arisheva OS, Garmash IV, et al. Diagnosis of liver fibrosis in patients with heart failure. Klinicheskaja farmakologija i terapija. 2017;26(3):7–12. (In Russ.)

[114] Балашова А.А., Аришева О.С., Гармаш И.В. и др. Фиброз печени: методы диагностики и возможности оценки при сердечной недостаточности // Клиническая фармакология и терапия. 2017. Т. 26, № 3. С. 7–12.

RIGHTS & PERMISSIONS

Kisliuk K.A., Bogdanov A.N., Shcherbak S.G., Apalko S.V.